ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,499 | -51.4% | 9,982 | -7.0% | 0.00% | 0.0% |
| Q2 2023 | $229,579 | -47.7% | 10,728 | -1.2% | 0.00% | -66.7% |
| Q1 2023 | $439,138 | -11.3% | 10,859 | +2.1% | 0.00% | 0.0% |
| Q4 2022 | $494,833 | -11.0% | 10,637 | -0.8% | 0.00% | -25.0% |
| Q3 2022 | $556,000 | +11.6% | 10,720 | +1.8% | 0.00% | +33.3% |
| Q2 2022 | $498,000 | -37.0% | 10,526 | -5.3% | 0.00% | -25.0% |
| Q1 2022 | $791,000 | -9.0% | 11,118 | -4.3% | 0.00% | 0.0% |
| Q4 2021 | $869,000 | +27.6% | 11,617 | -3.1% | 0.00% | 0.0% |
| Q3 2021 | $681,000 | +24.7% | 11,988 | -3.3% | 0.00% | +100.0% |
| Q2 2021 | $546,000 | -12.9% | 12,395 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $627,000 | +17.2% | 12,713 | -0.0% | 0.00% | 0.0% |
| Q4 2020 | $535,000 | -10.4% | 12,716 | -2.5% | 0.00% | -33.3% |
| Q3 2020 | $597,000 | -10.0% | 13,037 | -1.2% | 0.00% | 0.0% |
| Q2 2020 | $663,000 | +0.8% | 13,198 | +3.1% | 0.00% | -25.0% |
| Q1 2020 | $658,000 | -13.2% | 12,795 | +4.2% | 0.00% | +33.3% |
| Q4 2019 | $758,000 | +0.3% | 12,277 | -2.5% | 0.00% | 0.0% |
| Q3 2019 | $756,000 | -29.6% | 12,589 | -1.1% | 0.00% | -25.0% |
| Q2 2019 | $1,074,000 | -10.4% | 12,726 | +1.5% | 0.00% | -20.0% |
| Q1 2019 | $1,198,000 | +31.4% | 12,539 | -2.7% | 0.01% | +25.0% |
| Q4 2018 | $912,000 | -18.1% | 12,881 | -1.1% | 0.00% | 0.0% |
| Q3 2018 | $1,113,000 | -24.0% | 13,026 | +3.1% | 0.00% | -20.0% |
| Q2 2018 | $1,464,000 | +82.3% | 12,633 | +27.3% | 0.01% | +66.7% |
| Q1 2018 | $803,000 | +12.3% | 9,921 | -18.6% | 0.00% | +50.0% |
| Q4 2017 | $715,000 | +25.9% | 12,187 | +0.4% | 0.00% | 0.0% |
| Q3 2017 | $568,000 | +38.2% | 12,139 | +6.4% | 0.00% | +100.0% |
| Q2 2017 | $411,000 | +38.9% | 11,413 | +18.7% | 0.00% | 0.0% |
| Q1 2017 | $296,000 | -20.9% | 9,614 | -13.9% | 0.00% | 0.0% |
| Q4 2016 | $374,000 | -99.9% | 11,170 | -1.4% | 0.00% | 0.0% |
| Q3 2016 | $301,305,000 | +21.7% | 11,323 | +0.9% | 0.00% | 0.0% |
| Q2 2016 | $247,489,000 | -27.4% | 11,224 | -3.4% | 0.00% | 0.0% |
| Q1 2016 | $341,000,000 | -7.3% | 11,619 | +4.3% | 0.00% | -50.0% |
| Q4 2015 | $368,000,000 | +90540.4% | 11,135 | -0.9% | 0.00% | 0.0% |
| Q3 2015 | $406,000 | -99.9% | 11,237 | +17.3% | 0.00% | 0.0% |
| Q2 2015 | $431,049,000 | +110.1% | 9,581 | +43.0% | 0.00% | +100.0% |
| Q1 2015 | $205,123,000 | -38.9% | 6,699 | +1.5% | 0.00% | 0.0% |
| Q4 2014 | $335,559,000 | +25.5% | 6,599 | -2.3% | 0.00% | 0.0% |
| Q3 2014 | $267,335,000 | -8.2% | 6,756 | -0.1% | 0.00% | 0.0% |
| Q2 2014 | $291,196,000 | +194.2% | 6,761 | +173.2% | 0.00% | – |
| Q1 2014 | $98,975,000 | +50.2% | 2,475 | +2.4% | 0.00% | – |
| Q4 2013 | $65,908,000 | +17.9% | 2,416 | -1.0% | 0.00% | – |
| Q3 2013 | $55,925,000 | – | 2,440 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |